FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149782162> ?p ?o ?g. }

• W3149782162 endingPage "838" @default.
• W3149782162 startingPage "831" @default.
• W3149782162 abstract "•Most COVID-19 patients with normal troponin and BNP had no urgent TTE findings.•Troponin and BNP may help determine which patients can safely delay TTE. BackgroundPatients hospitalized with coronavirus disease 2019 (COVID-19) often have abnormal findings on transthoracic echocardiography (TTE). However, although not all abnormalities on TTE result in changes in clinical management, performing TTE in recently infected patients increases disease transmission risks. It remains unknown whether common biomarker tests, such as troponin and B-type natriuretic peptide (BNP), can help distinguish in which patients with COVID-19 TTE may be safely delayed until infection risks subside.MethodsUsing electronic health records data and chart review, the authors retrospectively studied all patients hospitalized with COVID-19 in a multisite health care system from March 1, 2020, to January 15, 2021, who underwent TTE within 14 days of their first positive COVID-19 result and had BNP and troponin measured before or within 7 days of TTE. The primary outcome was the presence of one or more urgent echocardiographic findings, defined as left ventricular ejection fraction ≤ 35%, wall motion score index ≥ 1.5, moderate or greater right ventricular dysfunction, moderate or greater pericardial effusion, intracardiac thrombus, pulmonary artery systolic pressure > 50 mm Hg, or at least moderate to severe valvular disease. Stepwise logistic regression was conducted to determine biomarkers and comorbidities associated with the outcome. The performance of a rule for classifying TTE using troponin and BNP was evaluated.ResultsFour hundred thirty-four hospitalized and 151 intensive care unit patients with COVID-19 were included. Urgent findings on TTE were present in 105 patients (24.2%). Troponin and BNP were abnormal in 311 (71.7%). Heart failure (odds ratio, 5.41; 95% CI, 2.61–11.68), troponin > 0.04 ng/mL (odds ratio, 4.40; 95% CI, 2.05–10.05), and BNP > 100 pg/mL (odds ratio, 5.85; 95% CI, 2.35–16.09) remained significant predictors of urgent findings on TTE after stepwise selection. No urgent findings on TTE were seen in 95.1% of all patients and in 91.3% of intensive care unit patients with normal troponin and BNP.ConclusionsTroponin and BNP were highly associated with urgent echocardiographic findings and may be used in triaging algorithms for determining in which patients TTE can be safely delayed until after their peak infectious window has passed. Patients hospitalized with coronavirus disease 2019 (COVID-19) often have abnormal findings on transthoracic echocardiography (TTE). However, although not all abnormalities on TTE result in changes in clinical management, performing TTE in recently infected patients increases disease transmission risks. It remains unknown whether common biomarker tests, such as troponin and B-type natriuretic peptide (BNP), can help distinguish in which patients with COVID-19 TTE may be safely delayed until infection risks subside. Using electronic health records data and chart review, the authors retrospectively studied all patients hospitalized with COVID-19 in a multisite health care system from March 1, 2020, to January 15, 2021, who underwent TTE within 14 days of their first positive COVID-19 result and had BNP and troponin measured before or within 7 days of TTE. The primary outcome was the presence of one or more urgent echocardiographic findings, defined as left ventricular ejection fraction ≤ 35%, wall motion score index ≥ 1.5, moderate or greater right ventricular dysfunction, moderate or greater pericardial effusion, intracardiac thrombus, pulmonary artery systolic pressure > 50 mm Hg, or at least moderate to severe valvular disease. Stepwise logistic regression was conducted to determine biomarkers and comorbidities associated with the outcome. The performance of a rule for classifying TTE using troponin and BNP was evaluated. Four hundred thirty-four hospitalized and 151 intensive care unit patients with COVID-19 were included. Urgent findings on TTE were present in 105 patients (24.2%). Troponin and BNP were abnormal in 311 (71.7%). Heart failure (odds ratio, 5.41; 95% CI, 2.61–11.68), troponin > 0.04 ng/mL (odds ratio, 4.40; 95% CI, 2.05–10.05), and BNP > 100 pg/mL (odds ratio, 5.85; 95% CI, 2.35–16.09) remained significant predictors of urgent findings on TTE after stepwise selection. No urgent findings on TTE were seen in 95.1% of all patients and in 91.3% of intensive care unit patients with normal troponin and BNP. Troponin and BNP were highly associated with urgent echocardiographic findings and may be used in triaging algorithms for determining in which patients TTE can be safely delayed until after their peak infectious window has passed." @default.
• W3149782162 created "2021-04-13" @default.
• W3149782162 creator A5040204150 @default.
• W3149782162 creator A5055685745 @default.
• W3149782162 creator A5067437326 @default.
• W3149782162 creator A5075579668 @default.
• W3149782162 date "2021-08-01" @default.
• W3149782162 modified "2023-09-30" @default.
• W3149782162 title "Determining Which Hospitalized Coronavirus Disease 2019 Patients Require Urgent Echocardiography" @default.
• W3149782162 cites W2057780602 @default.
• W3149782162 cites W2058384798 @default.
• W3149782162 cites W2111992555 @default.
• W3149782162 cites W2142276326 @default.
• W3149782162 cites W2146503455 @default.
• W3149782162 cites W2647973374 @default.
• W3149782162 cites W2788653990 @default.
• W3149782162 cites W2985852915 @default.
• W3149782162 cites W3009885589 @default.
• W3149782162 cites W3012756997 @default.
• W3149782162 cites W3013231340 @default.
• W3149782162 cites W3014099229 @default.
• W3149782162 cites W3014596382 @default.
• W3149782162 cites W3014654774 @default.
• W3149782162 cites W3015425066 @default.
• W3149782162 cites W3022663832 @default.
• W3149782162 cites W3025204546 @default.
• W3149782162 cites W3028583791 @default.
• W3149782162 cites W3028755072 @default.
• W3149782162 cites W3033372164 @default.
• W3149782162 cites W3033399055 @default.
• W3149782162 cites W3034144687 @default.
• W3149782162 cites W3034166785 @default.
• W3149782162 cites W3035765544 @default.
• W3149782162 cites W3036054066 @default.
• W3149782162 cites W3045873506 @default.
• W3149782162 cites W3048083373 @default.
• W3149782162 cites W3049206116 @default.
• W3149782162 cites W3082491158 @default.
• W3149782162 cites W3093590865 @default.
• W3149782162 cites W3094124478 @default.
• W3149782162 doi "https://doi.org/10.1016/j.echo.2021.03.010" @default.
• W3149782162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8012271" @default.
• W3149782162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33812952" @default.
• W3149782162 hasPublicationYear "2021" @default.
• W3149782162 type Work @default.
• W3149782162 sameAs 3149782162 @default.
• W3149782162 citedByCount "8" @default.
• W3149782162 countsByYear W31497821622021 @default.
• W3149782162 countsByYear W31497821622022 @default.
• W3149782162 countsByYear W31497821622023 @default.
• W3149782162 crossrefType "journal-article" @default.
• W3149782162 hasAuthorship W3149782162A5040204150 @default.
• W3149782162 hasAuthorship W3149782162A5055685745 @default.
• W3149782162 hasAuthorship W3149782162A5067437326 @default.
• W3149782162 hasAuthorship W3149782162A5075579668 @default.
• W3149782162 hasBestOaLocation W31497821621 @default.
• W3149782162 hasConcept C126322002 @default.
• W3149782162 hasConcept C164705383 @default.
• W3149782162 hasConcept C2778198053 @default.
• W3149782162 hasConcept C2781175549 @default.
• W3149782162 hasConcept C36036425 @default.
• W3149782162 hasConcept C500558357 @default.
• W3149782162 hasConcept C71924100 @default.
• W3149782162 hasConcept C78085059 @default.
• W3149782162 hasConceptScore W3149782162C126322002 @default.
• W3149782162 hasConceptScore W3149782162C164705383 @default.
• W3149782162 hasConceptScore W3149782162C2778198053 @default.
• W3149782162 hasConceptScore W3149782162C2781175549 @default.
• W3149782162 hasConceptScore W3149782162C36036425 @default.
• W3149782162 hasConceptScore W3149782162C500558357 @default.
• W3149782162 hasConceptScore W3149782162C71924100 @default.
• W3149782162 hasConceptScore W3149782162C78085059 @default.
• W3149782162 hasFunder F4320332161 @default.
• W3149782162 hasFunder F4320337338 @default.
• W3149782162 hasIssue "8" @default.
• W3149782162 hasLocation W31497821621 @default.
• W3149782162 hasLocation W31497821622 @default.
• W3149782162 hasOpenAccess W3149782162 @default.
• W3149782162 hasPrimaryLocation W31497821621 @default.
• W3149782162 hasRelatedWork W128809133 @default.
• W3149782162 hasRelatedWork W2041991364 @default.
• W3149782162 hasRelatedWork W2092286633 @default.
• W3149782162 hasRelatedWork W2618254838 @default.
• W3149782162 hasRelatedWork W3133762537 @default.
• W3149782162 hasRelatedWork W3158482145 @default.
• W3149782162 hasRelatedWork W3203913864 @default.
• W3149782162 hasRelatedWork W4321610430 @default.
• W3149782162 hasRelatedWork W4366000060 @default.
• W3149782162 hasRelatedWork W4381197018 @default.
• W3149782162 hasVolume "34" @default.
• W3149782162 isParatext "false" @default.
• W3149782162 isRetracted "false" @default.
• W3149782162 magId "3149782162" @default.
• W3149782162 workType "article" @default.